(Q44439560)

English

Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial

scientific article published on January 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 December 2017

Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial (English)

1 reference

Europe PubMed Central

3 December 2017

Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial (English)

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Methicillin Resistance

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12744768

2 January 2024

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

author name string

Jim Zhiming Li

1

1 reference

Europe PubMed Central

3 December 2017

Richard J. Willke

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12744768

2 January 2024

Brian E. Rittenhouse

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12744768

2 January 2024

Michael J. Rybak

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12744768

2 January 2024

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2003

1 reference

Europe PubMed Central

3 December 2017

full work available at URL

https://www.liebertpub.com/doi/pdf/10.1089/109629603764655290

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Surgical Infections

1 reference

Europe PubMed Central

3 December 2017

4

1 reference

Europe PubMed Central

3 December 2017

1

1 reference

Europe PubMed Central

3 December 2017

57-70

1 reference

Europe PubMed Central

3 December 2017

Optimal treatment of complicated skin and skin structure infections

1

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

An overview of nosocomial infections, including the role of the microbiology laboratory

2

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Preventing surgical site infections: a surgeon's perspective

3

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Surgical site infection surveillance

4

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve

5

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Soft tissue infections

6

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Colonisation and infection with resistant gram-positive cocci. Epidemiology and risk factors.

7

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

8

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Overview of resistance in the 1990s

9

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTR

10

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.

11

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Staphylococcus aureus and vancomycin: the sequel

12

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms

13

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Resistance patterns among nosocomial pathogens: trends over the past few years

14

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk

15

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998.

16

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community.

17

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Emergence of methicillin-resistant Staphylococcus aureus as a community pathogen

18

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998.

19

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco

20

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections.

21

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

22

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs?

23

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

The economic impact of Staphylococcus aureus infection in New York City hospitals

24

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

American Society for Microbiology

25

742

author name string

Welch KE

publication date

1999

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy.

28

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Recurrent Staphylococcus aureus bacteremia

29

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

30

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin.

31

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

A novel antimicrobial agent joins the battle against resistant bacteria

32

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Linezolid: an oxazolidinone antimicrobial agent

33

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

34

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Linezolid: a review of its use in the management of serious gram-positive infections

35

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

36

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

37

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

38

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group

39

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

40

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative gram-positive infections

41

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

42

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

A new look at the statistical model identification

44

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Pharmacokinetics and tissue penetration of linezolid following multiple oral doses

45

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil

46

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics

47

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis

48

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Early Switch From Intravenous to Oral Antibiotics and Early Hospital Discharge

49

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Use of insurance claims data to assess outpatient antimicrobial therapy for gram-positive infections

50

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Cost perspectives for outpatient intravenous antimicrobial therapy

51

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Early discharge of infected patients through appropriate antibiotic use.

52

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy

53

1 reference

10.1089/109629603764655290

https://api.crossref.org/works/10.1089/109629603764655290

2 January 2024

Identifiers

10.1089/109629603764655290

1 reference

Europe PubMed Central

3 December 2017

1 reference

Europe PubMed Central

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44439560&oldid=2042931404"